Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

UNCOVERED: Avita medical modifies barda contract for recell system in soft tissue reconstruction - The Untold Story

Biomedical Advanced Research and Development Authority (BARDA) has modified its contract with AVITA Medical Inc (NASDAQ:RCEL) to support its clinical trial in soft tissue reconstruction. 

  • AVITA Medical is currently completing a pivotal trial to use the RECELL System for soft tissue reconstruction.
  • Currently, the RECELL System is indicated in the U.S. to treat acute thermal burns.
  • Related: AVITA Medical Inks Supply Pact With Premier For RECELL System.
  • The clinical trial will compare the clinical performance of conventional autografting to that of widely meshed autografting with the RECELL System on acute non-burn full-thickness skin defects to demonstrate that less donor skin is needed without compromising healing outcomes. 
  • Topline data from the trial will be shared later this year.
  • Price Action: RCEL shares closed 4.09% lower at $7.74 on Monday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.